Lupin Signs Exclusive Licensing Agreement for YUVEZZI in Europe

Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland

/PRNewswire/ -- Global pharma major Lupin Limited ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that VISUfarma...

Lupin signs exclusive licensing agreement for YUVEZZI in Europe

Lupin has announced that VISUfarma B.V. (VISUfarma), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited (Tenpoint). Under the agreement, VISUfarma will hold exclusive rights to undertake regulatory activities, commercialisation, marketing, promotion, distribution and sale of YUVEZZI (carbachol and brimonidin…

Lupin and Tenpoint Therapeutics Partner to Commercialize YUVEZZI Presbyopia Eye Drop in Europe

(PRESS RELEASE) MUMBAI/NAPLES, FL — Global pharma major Lupin Limited (“Lupin”) announced that VISUfarma B.V. (“VISUfarma”), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited (“Tenpoint”). This partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketi…

Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize Yuvezzi

VISUfarma, a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics, a wholly owned subsidiary of Tenpoint Therapeutics, according to an announcment from Lupin. The partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution, and sale of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% …